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Atrial Fibrillation and Heart Failure: Factors influencing the choice of oral 
anticoagulant 
 
Abstract  
 
Atrial fibrillation (AF) and heart failure (HF) frequently coexist. AF is identified in 
approximately one third of patients with HF and is linked to increased morbidity and 
mortality than from either condition alone. AF is relatively more common in HF with 
preserved ejection fraction (HFpEF) than with reduced ejection fraction (HFrEF). 
Nevertheless, the risk of stroke and systemic embolism (SSE) is significantly increased with 
both HF types and the absolute risk is heavily influenced by the presence and severity of 
associated additional stroke risk factors. The European Society of Cardiology has very 
recently introduced a third HF subtype entitled HF with mid-range ejection fraction 
(HFmrEF). At present oral anticoagulation is recommended for all patients with AF and HF, 
independent of HF type. In addition to warfarin there are currently four non-vitamin K oral 
anticoagulants (NOACs, previously called novel oral anticoagulants) that have been approved 
for the prevention of SSE.  They consist of one direct thrombin inhibitor, dabigatran and 
three factor Xa inhibitors: rivaroxaban, apixaban and, most recently, edoxaban. In this review 
article we present an overview of the evidence to support the use of NOACs for the 
prevention of SSE in patients with AF and HF and review the influence of HF subtype and 
co-morbidities on the potential choice of oral anticoagulant.  
  
Introduction 
 
Atrial fibrillation (AF) is the most commonly diagnosed sustained cardiac arrhythmia in 
adults. With better survival among persons with cardiovascular disease and an aging 
population, it is becoming an increasing health burden, affecting 2% of those under 65 years 
old, rising to 9% in those over 65, and 1 in 4 persons over their lifetime. [1-3]. In 2010 over 
33 million people worldwide had a diagnosis of AF. [4] 
 
AF frequently co-exists with heart failure (HF) [5]. Of patients diagnosed with AF, over 35% 
will subsequently be diagnosed with HF and vice versa [5,6]. Both conditions are risk factors 
for stroke and systemic embolism (SSE), and when combined have much worse outcomes 
[3,5,7,8].  Where AF and HF coexist, oral anticoagulation is recommended to reduce the 
associated SSE risk [8,9]. With the availability of an increasing number of Non-Vitamin K 
Oral Anticoagulants (NOACs, previously known as novel oral anticoagulants) in addition to 
warfarin the potential choice of oral anticoagulant has significantly broadened. In this article 
we will examine whether HF subtype influences both stroke risk and choice of oral 
anticoagulant. 
 
Atrial Fibrillation and Heart Failure 
 
HF and AF share many similar risk factors including hypertension, coronary artery disease 
and increasing age, accounting to some extent for their frequency of occurrence together.  
However, HF in itself may predispose to the development of AF, with various proposed 
mechanisms including impaired left ventricular filling and atrial remodelling [10,11]. In 
addition, AF can lead to HF by causing a tachymyopathy, and can worsen the severity of HF 
symptoms. [9,12,13]. In each condition, the development of the second is associated with 
increased morbidity and mortality, leading to more frequent, and longer, hospitalisation. [14-
16]. The proportion of those with HF who also have AF increases with New York Heart 
Association (NYHA) class, from 5% in NYHA I to 49% in NYHA IV [17]. 
 
Heart Failure Subtypes and Atrial Fibrillation 
 
HF syndrome has traditionally been divided into two broad subtypes by assessment of left 
ventricular function and ejection fraction (EF):  HF with reduced ejection fraction (HFrEF), 
and HF with preserved ejection fraction (HFpEF, of which diastolic heart failure is a 
subgroup), with each accounting for approximately half of the HF population depending on 
the population studied. [18-20]. The European Society of Cardiology has very recently 
defined a third HF subgroup called HF with mid-range ejection fraction (HFmrEF).  This new 
term refers to patients fulfilling the clinical features (symptoms and signs of heart failure) and 
a left ventricular ejection fraction of 40-49% with HFpEF referring to an ejection fraction of 
>50% [21]. This group has been included to stimulate future research and better define the 
grey area around ejection fractions of 40-49% on the fringes of both HFrEF and HFpEF.   
 
Whilst the risk of AF is increased with all types of HF, the relative risk is greater with HFpEF 
than that for HFrEF reflecting the greater burden of AF risk factors, such as advanced age, 
obesity and hypertension in the former [18,20, 22-24]. Moreover, recent data has shown that 
HFpEF is more often characterised by increased LA stiffness and HFrEF by greater eccentric 
LA remodelling, further explaining the unequal AF burden between the two HF subtypes 
[11]. Whilst the rates of SSE, hospitalisation and HF symptom progression appear to be 
broadly similar in HFpEF and HFrEF with AF, mortality is marginally yet significantly 
higher in HFrEF [18,25,26]. In fact, in a recently published meta-analysis of >30,000 patients 
with coexisting AF and HF, it was shown that all-cause mortality was significantly higher in 
AF with HFrEF (risk ratio [RR] 1.24, 95% CI 1.12-1.36, p<0.001) [26].  
 
Stroke Risk in Atrial Fibrillation and Heart Failure 
 
AF is a common risk factor for stroke and systemic embolism (SSE), and has been shown to 
confer a hypercoagulable state which is heavily influenced by the number and type of 
associated risk factors [27,28].  AF results in increased thrombotic risk via all components of 
Virchow’s triad: Abnormalities of blood flow (due to reduced atrial kick), the vessel wall 
(with endothelial injury) and hypercoagulability (activation of platelets and clotting factors) 
have all been demonstrated in AF [28-30]. The loss of systole within the atria results in 
comparative stasis, which may be worsened by increased ventricular rate and decreasing left 
atrial filling with HF [28].  This particularly affects the left atrial appendage (LAA) which is 
the most common site of thrombus formation [31].  AF confers a five-fold increase in stroke 
risk across all ages, and it is estimated that with increasing age up to 24% of strokes are 
secondary to AF, with these tending to be larger strokes with more disabling symptoms and 
worse outcomes. [3,8]  
 
HF has been shown to be an independent risk factor for stroke in AF and the presence of both 
conditions together leads to an increase in stroke severity and all-cause mortality [5,7,32,33]. 
Stroke in HF is most commonly associated with AF, however there is evidence that HF ‘per 
se’ even in the absence of AF also confers a hypercoagulable state [34,35]. Data from a 
recent meta-analysis comparing outcomes of patients with atrial fibrillation and HFrEF 
versus HFpEF have demonstrated that there were no significant differences in the risk of 
stroke between the two (RR 0.85, 95% CI 0.70-1.03, p=0.094) [26]. However, there was 
marked variation in the definitions of HFpEF which varied from a left ventricular ejection 
fraction of >40% to >50%. [26]. Nevertheless this data would suggest that a diagnosis of 
heart failure is the key determinant of stroke risk rather than subtype and is further supported 
by real world observational data  [36].  
 
Whilst there remains little evidence of any benefit from anticoagulation in lone HF without 
AF [37,38], the case for anticoagulation in AF is well established [9].  In addition to 
decreasing the risk of SSE, anticoagulation in patients hospitalised with HF and AF has also 
been show to result in decreased mortality and readmission rates [39]. 
 
Stroke risk in HF was thought to increase with worsening left ventricular (LV) dysfunction 
(LVSD) [40-43].  However, more recent studies of the HF population have demonstrated no 
difference in risk of stroke or embolic events associated with either LVSD 
(mild/moderate/severe) or NHYA class [44,45].   
 
Stroke and bleeding risk scoring in AF and HF 
 
Several scoring systems have been developed to estimate thromboembolic risk associated 
with AF [27,46]. The CHA2DS2VASc assessment is the most widely used system and has 
been incorporated into the majority of contemporaneous guidelines [8,9].  Within its 
validation HF was typically defined as either symptomatic HF episode or evidence of LV 
dysfunction [46].  Given that inclusion could be based on clinical HF without assessment of 
LV function, it likely that patients with both HFrEF and HFpEF were included. 
 
The benefit of anticoagulation to reduce stroke risk needs to be carefully balanced with the 
increased risk of bleeding related to oral anticoagulation. Whilst many bleeding risk scoring 
systems are available, HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, 
Bleeding history or predisposition, Labile INR, Elderly and Drugs/alcohol) is perhaps the 
easiest to use and has gained the greatest widespread current acceptance [8,9,47,48].  No 
HAS-BLED score represents an absolute contraindication to anticoagulation, however a score 
> 3 identifies those at highest bleeding risk and should alert clinicians to address any 
modifiable bleeding risk factors.  
 
Oral Anticoagulation 
 
Warfarin 
 
Until recently, Vitamin K antagonists (VKAs), principally warfarin, were the primary method 
of oral anticoagulation in atrial fibrillation.  Warfarin has been shown to be more effective 
than either placebo or single and dual antiplatelet therapy in lowering the risk of stroke 
[49,50].  Meta-analysis of randomised controlled trials has shown that warfarin leads to a 
64% decrease in the risk of SSE compared to placebo, and 39% compared to antiplatelet 
agents [49]. 
 
Whilst warfarin has been shown to be effective in reducing SSE risk, there are problems in its 
use. A narrow therapeutic window, slow onset and offset, and multiple food and drug 
interactions mean that the time spent in therapeutic range is low, undermining its efficacy. 
[51,52].  This is more of a problem in HF, where patients have been shown to persistently 
spend less time in therapeutic range than those with AF alone [53]. Other factors often 
associated with HF such as a high burden of additional medication, and frequent hospital 
admissions, have also been shown to predict poor INR control [53,54]. 
 
Four NOACs have been licensed for use in stroke prevention in patients with non-valvular 
AF (NVAF).  All have fixed doses and do not require regular blood tests for efficacy 
monitoring and therefore present an attractive alternative to warfarin in terms of ease of use.  
In addition, they provide a consistent and rapid onset/offset of anticoagulation and lack the 
number of food and drug interactions that undermine warfarin [9,55]. Their extended licences 
to include other conditions that not infrequently co-exist with AF such as thromboembolic 
disease have also further enhanced their use. 
 
Dabigatran 
 
The first of the NOACs to market, dabigatran is the only currently available oral direct 
thrombin inhibitor.  The initial RE-LY trial, published in 2009, compared open label warfarin 
with two blinded doses of dabigatran, 110mg and 150mg BD [56]. Both doses were shown to 
be non-inferior to warfarin in prevention of SSE.  Subsequently, data for participants with HF 
have been published in a subgroup analysis. [57]. 
 
From a total of 18113 patients in the RE-LY trial, 4904 patients were classified as having HF 
for subgroup analysis. HF was defined as the presence of NYHA class II or higher symptoms 
in the six months before screening, in patients with history of previous admission for 
congestive HF.  Within this subgroup, similar findings to the overall trial were found with 
respect to primary outcomes of SSE and safety with both doses of dabigatran being non-
inferior to warfarin with respect to the primary end point of SSE.  Annual rates of SSE were 
1.92% for warfarin, 1.9% for 110mg dabigatran (hazard ratio (HR) 0.99, 95% confidence 
interval (CI) 0.69-1.42) and 1.44% for 150mg dabigatran (HR 0.75, 95% CI 0.51-1.10). The 
rates of major bleeding were also consistent with the main trial and were not influenced by 
HF symptom class (NYHA II versus III, IV) or type (ejection fraction >40% versus <40%) (P 
for interaction not significant).  However, intracranial bleeding was significantly lower for 
both dabigatran dosages compared with warfarin (dabigatran 110 mg vs. warfarin (HR 0.34, 
95% CI 0.14–0.80; dabigatran 150 mg vs. warfarin, HR 0.39, 95% CI 0.17–0.89) [57].  
 
As expected the SSE rates were numerically higher in patients with HF irrespective of their 
allocated treatment (1.75% per year vs. 1.35%) and HF remained as an independent and 
powerful independent predictor of both vascular death (adjusted HR 2.26, 95% CI 1.96–2.61) 
and all-cause hospitalization (adjusted HR 1.13, 95% CI 1.07–1.20 per year)  
 Rivaroxaban 
 
Rivaroxaban is a direct factor Xa inhibitor and the second NOAC to obtain a licence for the 
prevention of SSE. Its key efficacy data is derived from the ROCKET AF trial [58]. This was 
an international, multicentre, double blind, double dummy, randomised non-inferiority trial of 
20mg OD dosing of rivaroxaban (15mg in defined groups) vs. warfarin in 14,264 patients 
with NVAF. In ROCKET 9033 (63.7%) patients had HF, which was defined as either a 
history of HF or a left ventricular EF <40% [59].  Rivaroxaban was noted to be non-inferior 
to warfarin and its efficacy for SSE prevention was consistent with the main trial in those 
with HF (1.90 versus 2.09%) and without HF (2.10 versus 2.54%; P-interaction=0.62) [59]. 
The risk of major or non-major clinically relevant bleeding with rivaroxaban was also similar 
to warfarin irrespective of HF history (P-interaction=0.99). The significant reduction in 
haemorrhagic stroke that was observed in the main trial was maintained in those with HF 
(adjusted HR, 0.38; 95% CI, 0.19-0.76; P-interaction=0.067). Consistent with previously 
published data the efficacy of rivaroxaban was not influenced by ejection fraction (<40 or ≥ 
40%; P-interaction=0.38) or NYHA class (I-II versus III-IV; P-interaction=0.68).  
 
Apixaban 
 
Apixaban is an oral direct factor Xa inhibitor and the third NOAC to be approved for the 
prevention of SSE in AF.  The key evidence in support of apixaban vs. warfarin for the 
prevention of SSE in AF was from the ARISTOTLE trial, which was a double-blind, double-
dummy randomized trial comparing twice daily dosage of 5mg oral apixaban (2.5mg with 
key lower dosing criteria) with warfarin, in 18201 patients with AF and CHADS2 Score >1 
[60].  This showed apixaban to be superior to warfarin in preventing SSE, in addition 
resulting in fewer bleeds and lower mortality [60].   
 
From ARISTOTLE, for patients where EF and HF status were known, three groups were 
defined.  Those with EF >40% and no HF symptoms (n=8728), a group with EF >40% and 
HF symptoms (n=2971), referred to as HFpEF, and a third group with EF ≤40% with or 
without HF symptoms (n=2736), referred to as left ventricular systolic dysfunction (LVSD) 
[61]. In patients with LVSD, apixaban was shown to be favourable to warfarin in the primary 
outcome of SSE (annual rate 0.99% vs. 1.80%, HR 0.55,) and in all other efficacy end points 
including major, or clinical relevant bleeding (rate 5.05 vs. 6.01%, HR 0.84), ISTH major 
bleeding (2.77 versus 3.41; HR 0.81), total and intracranial bleeding. Within the HFpEF 
group, apixaban was comparable or preferable to warfarin in primary outcome, efficacy 
endpoints and safety outcomes other than gastrointestinal bleeding (rate 1.08% vs. 0.53%, 
HR 2.03) which was the only endpoint where there was a notable interaction by group 
(LVSD, HFpEF and no HF) with a higher event rate in the apixaban versus warfarin group 
(P- interaction 0.043). 
 
Edoxaban 
 
Edoxaban is the most recent oral anticoagulant to the market, and is a direct factor Xa 
inhibitor.  The randomised, double blind, double dummy ENGAGE AF trial published in 
2013 compared warfarin with once daily high (60mg down to 30mg) and low (30mg down to 
15mg) dose edoxaban in patients with AF and a CHADS2 score of >2 [62].  Of the 21,205 
patients in the ENGAGE-AF Study, 12,124 (57.4%) were recorded to have HF, which was 
defined as the current presence or prior history of HF class C (structural heart disease with 
prior or current symptoms or HF such as shortness of breath, fatigue or decreased exercise 
tolerance) or class D (refractory HF requiring specialised interventions) [63]. Both high dose 
(annual rate 1.18%, HR 0.79 p<0.001) and low dose (annual rate 1.61%, HR 1.07, p=0.005) 
edoxaban were shown to be non-inferior to warfarin (annual rate 1.50%) in reducing the 
primary endpoint of SSE.   
 
The rate of major bleeding was 3.43% in warfarin, 2.75% in high dose edoxaban (HR 0.80, 
p<0.001) and 1.61% in low dose edoxaban (HR 0.47, p<0.001).  The rate of gastrointestinal  
bleeding was highest in the high dose edoxaban group (1.51%) compared to warfarin (1.23%) 
but lowest in the low dose edoxaban group (0.82%). 
 
Meta-analysis of NOACs in HF 
 
A recent meta-analysis of the HF subgroups from the four key randomised trials of NOACs 
for the prevention of SSE endorses their efficacy in HF and consists of 19 122 patients treated 
with NOAC of which 13 384 receiving single-/high-dose NOAC regimens, and 13 390 who 
received  warfarin. [64]. Although no significant benefit was identified in individual trials, 
this analysis demonstrated that single/high-dose NOACs significantly reduced the risk of SSE 
by 14% (Odds ratio, OR 0.86; 95% CI .76-0.98: p=0.02). In addition, these regimens had a 
24% lower risk of major bleeding compared to warfarin (OR, 0.76, p<0.00001).  Low dose 
NOACs showed similar reductions in SSE to warfarin and a non-significant decrease in 
major bleeding risk. 
 Choice of anticoagulant in heart failure 
 
Current guidelines [8,9] advocate the use of anticoagulation for the prevention of SSE in AF 
with a CHA2DS2-VASc score >1 (unless 1 is due to female sex alone).  Therefore, all patients 
with HF and AF should be strongly considered for anticoagulation.  
 
The choice of agent in these patients is reliant on multiple factors and it is difficult to make 
direct comparisons across the four studies given their differences in trial design and study 
populations.  In addition, the published data for all four NOACS in HF is derived from 
observational data of subgroup analyses with definition of heart failure and available 
information about ejection fraction and symptoms varying widely, requiring consideration 
when applying this to patients on an individual basis.   
 
Does HF severity or presentation with HFPEF versus HFREF influence the choice of 
anticoagulant? 
 
 The NOAC trials have included both HFpEF and HFrEF and all categories of NYHA 
symptomatology.  As discussed above, the type of HF does not appear to influence the 
efficacy of anticoagulants, and therefore the choice of agent. However, there are differences 
in the usage and risk profile between agents that may come into play in selecting the agent 
used.  Patients with HF will frequently have other indications for anticoagulation that may 
need to be considered.  Patients with the newly defined heart failure category of HFmrEF 
[21] have not been studied in clinical practice and represent an avenue for future comparative 
studies in terms of stroke risk and anticoagulation efficacy in atrial fibrillation.  
 
Valvular heart disease  
 
Valvular heart disease is commonly found in patients with heart failure.  Definitions of 
valvular atrial fibrillation vary among consensus guidelines. The European Heart Rhythm 
Association EHRA) guidelines refer to AF occurring in the presence of mechanical heart 
valves, or moderate to severe mitral stenosis (usually of rheumatic origin) [65] whereas the 
American Heart Association (AHA) and the American College of Cardiology (ACC) 
guidance includes these categories, but also bioprosthetic valve replacements and mitral valve 
repair [8]. Patients with significant native valvular disease and prosthetic valves were 
excluded from the NOAC trials. 
 
Sub-analysis of the ARISTOTLE trial, however, has shown no significant difference in the 
effect of apixaban compared to warfarin in reducing SSE in those with or without non 
valvular (mechanical valves and significant mitral stenosis excluded) heart disease (HR 0.7 
and 0.84 respectively, P-interaction 0.38) with less bleeding (HR 0.79 and 0.65 respectively, 
P-interaction 0.23) [66]. This finding in terms of efficacy versus warfarin for the prevention 
of SSE  has also been endorsed by recently published sub-analyses of both the ROCKET and 
RE-LY studies in which important coexisting valvular disease was identified in 14.1% and 
21.8% of the study cohorts respectively [67,68].  
 
At present the EHRA recommends that NOACs should be avoided in patients with 
mechanical prosthetic valves and moderate-to-severe mitral stenosis where warfarin and oral 
vitamin K antagonists should be used. In the light of more recent data the EHRA suggests 
that NOACs can be used in patients with mild-to-moderate other native valvular disease and 
in severe aortic stenosis. The EHRA also state that NOACs can be used following both mitral 
valve repair and tissue valve replacements (excluding the first three months post operatively). 
They also support their use in hypertrophic cardiomyopathy, which is well recognised cause 
of HF, despite the recognised paucity of data [65].  
 
Patients with concomitant CAD 
 
Coronary artery disease is the leading risk factor for HFrEF and is observed in >50% of 
patients with HF, independent of subtype. Hence, it is not uncommon for there to be an 
indication for either single or dual antiplatelet therapy. Whilst it is well established that the 
concomitant use of any oral anticoagulant with either single or dual antiplatelet therapy 
dramatically increases bleeding risk the competing needs for both therapies is a not 
infrequent issue [69]. Phase III Trials looking at the use of NOACs in Acute Coronary 
Syndromes have demonstrated significantly higher risks of bleeding with both apixaban and 
rivaroxaban when combined with dual antiplatelet therapy. [70,71].  In the case of 
rivaroxaban, this effect was seen even with much lower doses (2.5mg BD) than used for the 
prevention of SSE.  
 
Where there is an indication for anticoagulation for SSE in AF, and separately an indication 
for single or dual antiplatelet treatment, decisions must be made on an individual patient basis 
carefully balancing the thrombotic versus bleeding risks. There is much greater experience 
with the use of warfarin in combination with dual anti-platelet therapy (triple therapy) than 
for the NOACs. There are also limited data from clinical trials on the use of NOACs in 
combination with clopidogrel and even less for newer antiplatelet agents such as prasugrel 
and ticagrelor. The increased major gastrointestinal bleeding rates observed with both 
dabigatran and rivaroxaban versus warfarin from RE-LY and ROCKET-AF respectively add 
to the concern. Despite its more favourable side effect profile, even in the double blinded 
randomised APPRAISE-2 study, apixaban at the lowest dose of 2.5 mg bd led an important 
increase in major and clinically relevant non-major bleeding (including gastrointestinal 
bleeding) versus placebo (hazard ratio, 1.78; 95% confidence interval, 0.91 to 3.48; P=0.09) 
in patients with acute coronary syndrome. Hence, where triple therapy is necessary use of a 
proton pump inhibitor is recommended and the period of triple therapy minimised to the 
shortest period possible without substantially compromising efficacy [65].  
 
Renal dysfunction 
 
Renal dysfunction is commonly found in HF with some epidemiological studies estimating 
that fewer than 10% of the HFrEF population have normal renal function [72]. The 
prevalence of renal dysfunction in those with HFpEF is estimated between 30-60% [73,74].  
Worsening HF (rising NYHA class) appears to be associated with worsening renal function.  
There is very limited data on the use of NOACs in patients with creatinine clearance <30 
ml/minute, and in most cases warfarin is thought to be preferable [65]. Where the use of a 
NOAC is felt to be necessary, NOACs with the lowest rate of renal clearance are preferable 
and dabigatran should be avoided. Where the estimated creatinine clearance is 15-29 it is the 
authors preference to use apixaban at 2.5mg BD.  [75].  
 
Left ventricular thrombus 
 
Warfarin and the Vitamin K antagonists have been the accepted standard oral anticoagulation 
in the treatment of left ventricular thrombus with or without atrial fibrillation, despite a 
paucity of evidence. Where atrial fibrillation and left ventricular thrombus exist it is the 
authors opinion that NOACs could be considered within their licensed indications (based on 
the CHA2DS2-VASC Sores) however, NOACs should be avoided in the absence of atrial 
fibrillation.  
 
Reversal agent  
 
An initial concern regarding the use of NOACs was the lack of reversal agent. However, in 
October 2015 the FDA approved the first reversal agent for dabigatran, idarucizumab. This 
followed trials demonstrating rapid reversal of anticoagulant effect within minutes both in 
patients requiring reversal for uncontrollable bleeding, and those where reversal was required 
for urgent surgery or invasive procedures [76].  The novel factor Xa inhibitor Andexanet has 
been shown to be highly effective at reversing the effects of both apixaban and rivaroxaban in 
a recent phase III trial of 67 patients presenting with acute major bleeding within 18 hours 
after the administration of a factor Xa inhibition. [77].  
 
Concomitant device therapy  
 
A potential additional benefit to NOACs in the context of HFrEF is their use in patients 
requiring pacemaker or ICD insertion.  Their rapid on- and offset of action allows for a short 
window where the procedure can be carried out without the need for bridging therapy.  
However, data gathered from centres adopting this approach has shown variability in both 
timings of discontinuation and rates of bleeding complications [78]. 
 
Conclusion 
 
HF and AF frequently coexist and the presence of HF increases the risk of SSE across all HF 
subtypes. The choice of OAC for the prevention of SSE has greatly increased in recent years 
and there are currently five agents to choose from with warfarin and four approved NOACs. 
Overall, the generally more favourable bleeding profile, and ease of use, without the 
requirement for frequent monitoring, in patients who are likely to already be on a significant 
number of other medications, favours NOACs for the majority of patients.  The choice 
NOAC is influenced by individual patient circumstances such as concomitant medication, 
renal function and the familiarity of the prescriber. While heart failure subtype may influence 
these factors, in itself it is not a determinant for the type of oral anticoagulant recommended.  
Table 1 – Distribution of heart failure patients amongst NOAC trials 
 Dabigatran   Rivaroxaban  Apixaban  Edoxaban 
Trial Re-LY ROCKET ARISTOTLE ENGAGE AF-
TIMI 48 
Trial Design  Randomised  
open label warfarin 
versus two blinded 
dabigatran doses  
Randomised  
double-blinded  
Randomised 
double-blinded 
Double-blind, 
double-dummy  
Main trial, n 18113 14,264 18201 21105 
Oral treatment doses  110mg or 150mg bid  20 mg/15mg od  5mg/2.5 bid   60mg vs. 30mg 
od 
Inclusion criteria CHADS2>1* CHADS2 >2 CHADS2>1 CHADS2>2 
HF population, n (%) 
(% of main study) 
-LVEF <40%, n (%) 
4904 (27.1%) 
 
856 (17.5%) 
9033 (63.7%) 
 
2145 (23.7%)  
5943 (32.7%) 
 
2736 (46.1%) 
12124 
 
NA  
NYHA Class 
I 
II 
IIII 
IV 
 
 
  74.3% (I/II) 
 
 25.7% (III/IV) 
 
13.2% 
55.5% 
27.8% 
1.5% 
 
21.2% 
56.3% 
21.5% 
0.9% 
 
    
   78.3% (I/II) 
 
   21.7% (III/IV) 
HF, Heart failure; SSE stroke and systemic embolism; NYHA, New York Heart Association; LVEF, left 
ventricular ejection fraction; *aged 65-74 years included if diabetes, hypertension or coronary artery disease; NA, 
not yet available (unpublished)  
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